GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Inhaled Fluticasone Furoate/Vilanterol Safety and Tolerability, PK and PD Study

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Fluticasone Furoate
Drug: Fluticasone Furoate/Vilanterol

First Posted Date: 2011-10-17

Last Posted Date: 2017-01-11

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 26

Registration Number: NCT01453023

Locations: 🇺🇸
GSK Investigational Site, Huntington Beach, California, United States

An Efficacy and Safety Study of Fixed-dose Rosiglitazone/Glimepiride to Treat Chinese Type 2 Diabetes Patients

Phase 3

Terminated

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: glimepiride
Drug: rosiglitazone/glimepiride fix dose combination

First Posted Date: 2011-10-17

Last Posted Date: 2012-03-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 86

Registration Number: NCT01453049

Locations: 🇨🇳
GSK Investigational Site, Wuhan, China

Phase IV Observational Study in Chronic Lymphocytic Leukemia

Completed

Conditions: Leukaemia, Lymphocytic, Chronic

Interventions: Drug: Arzerra

First Posted Date: 2011-10-17

Last Posted Date: 2014-07-08

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 1

Registration Number: NCT01453062

To Investigate the Effect of Intravenous Ondansetron on Cardiac Conduction as Compared to Placebo and Moxifloxacin in Healthy Adult Subjects

Phase 1

Completed

Conditions: Nausea and Vomiting, Chemotherapy-Induced

Interventions: Drug: ondansetron
Other: saline
Drug: moxifloxacin

First Posted Date: 2011-10-10

Last Posted Date: 2017-11-13

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 60

Registration Number: NCT01449188

Locations: 🇺🇸
GSK Investigational Site, Austin, Texas, United States

Phase I Study of Colistin Methanesulfonate Sodium

Phase 1

Completed

Conditions: Infections, Pseudomonas

Interventions: Drug: Saline
Drug: Colistimethate sodium

First Posted Date: 2011-10-10

Last Posted Date: 2017-07-21

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 22

Registration Number: NCT01449838

Locations: 🇦🇺
GSK Investigational Site, Randwick, New South Wales, Australia

An Investigation of the Pharmacokinetics of GSK961081 and Fluticasone Propionate in Healthy Volunteers

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: GSK961081 800 microgram dose
Drug: Fluticasone Propionate 500 microgram dose
Drug: GSK961081 800 microgram and Fluticasone Propionate 500 microgram separately
Drug: GSK961081 800 microgram Fluticasone Propionate 500 microgram in a blend